News

Phase III data for eye drug
Enlarge image

Clinical TrialsBelgium

Phase III data for eye drug

17.08.2012 - Belgian biopharmaceutical company ThromboGenics N.V. published encouraging data from two Phase III studies with its eye treatment experimental drug Ocriplasmin.

The studies published in New England Journal of Medicine (NEJM) including in total 652 patients found that the recombinant protein significantly resolved vitreomacular traction and closed macular holes compared to placebo in patients with vitreomacular adhesion (VMA). A health care practitioner, who treated patients in one of the studies said ocriplasmin could help a significant number of patients at an earlier point in their disease and improve their vision much more than surgery, which is the current standard of care.

"Results from the phase III programme with ocriplasmin are significant as they demonstrate the potential for using an enzymatic approach to resolve vitreomacular adhesion. This represents a real advance for patients living with vitreomacular adhesion who currently only have the option of surgery at a later stage of the disease," said Peter Stalmans, Department of Ophthalmology, University Hospitals, Leuven, Belgium. "The majority of patients who achieved resolution of their vitreomacular adhesion after a single intravitreal injection of ocriplasmin showed this positive outcome within the first seven days."

Ocriplasmin is a recombinant, truncated form of human plasmin that works by dissolving the proteins that link the vitreous to the macula. If approved, the drug, couldbecome the first pharmaceutical treatment for vitreomacular adhesion (VMA). Currently vitrectomy, or surgical removal of the vitreous from the eyeball, is the only available treatment for VMA. In patients with VMA, the vitreous adheres in an abnormally strong way to the retina, which can lead to traction on the retina, causing symptoms including impaired vision. Further unresolved traction may lead to the development of macular holes and central blindness.Thrombogenics developed the biologic and plans to market ocriplasmin on its own in the US. In a deal worth up to €300m in milestone payments and royalties Swiss drug maker Novartis’ subsidiary Alcon paid €75m up front in March to license the ex-US rights to the drug, which is currently under review by FDA and EMA.

http://www.european-biotechnology-news.com/news/news/2012-03/phase-iii-data-for-eye-drug.html

Stock marketsEU

29.01.2015 Denmark's Ascendis Pharma has successfully raised US$108m with its upsized NASDAQ IPO, while Irish animal health specialist Nexvet is waiting in the wings.

Contract ResearchEU

28.01.2015 EMA recommends suspending around 750 generic medicines marketed throughout the world after India’s GVK Biosciences is accused of faking bioequivalence studies. Meds considered critically important for patients will remain available.

RegulationEU

21.01.2015 The EMA is asking for comments on how to implement the transparency rules of EU Clinical Trial Regulation, pointing to the new clinical trial portal and database as the main instrument.

Stock marketsEUGermany

21.01.2015 2014 was a record year for biotech companies on the European stock market, with a total of €2.4bn raised in the year - 25% more than in the year before.

ResearchEUUK

20.01.2015 Ebola research projects are set to receive €215m in funding from the European Commission’s IMI2 Ebola+ programme. Among the project partners are vaccine developers Glaxosmithkline, Johnson&Johnson and Merck. 

Stock ExchangeUKDenmarkFrance

16.01.2015 It's time to get used to weekly IPO plans by European biotechs. UK's drug discovery firm Redx Pharma Ltd, established just five years ago, has come of age with their £80m (€105m) IPO plans.

M&ASwitzerland

14.01.2015 Pharma kingpin Roche has launched a billion-dollar transaction for a total of US$1.2bn (€1bn), taking over the majority of US cancer specialist Foundation Medicine.

PoliticsEU

14.01.2015 The European Parliament has backed the legislation allowing individual countries to restrict or prohibit the cultivation of genetically modified crops that have been authorised at EU level.

M&AIrelandUK

13.01.2015 Shire beefs up its rare disease portfolio after acquiring NPS Pharma with the aim of becoming a leading biotech in a US$5.2bn deal. Part of the deal is the US biotech's lead portfolio of gastrointestinal and hormone replacement therapies.

M&ASwitzerlandFrance

09.01.2015 The excitement surrounding CRISPR genome editing shows no sign of abating. This month, Novartis and US biotech Intellia Therapeutics became the first ever biotech-pharma collaboration to use the groundbreaking technology.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • FORMYCON13.90 EUR12.10%
  • MAGFORCE5.10 EUR7.82%
  • SANTHERA103.00 CHF5.64%

FLOP

  • CYTOS0.32 CHF-17.95%
  • CO.DON2.15 EUR-4.44%
  • MEDIGENE3.80 EUR-4.28%

TOP

  • ADDEX3.44 CHF48.3%
  • CYTOS0.32 CHF39.1%
  • FORMYCON13.90 EUR37.9%

FLOP

  • ACTELION100.70 CHF-13.3%
  • BIOFRONTERA2.02 EUR-12.2%
  • MOLOGEN5.72 EUR-9.9%

TOP

  • SANTHERA103.00 CHF2494.5%
  • BB BIOTECH248.45 EUR95.9%
  • FORMYCON13.90 EUR85.3%

FLOP

  • CYTOS0.32 CHF-91.2%
  • MOLOGEN5.72 EUR-50.5%
  • 4SC0.82 EUR-50.0%

No liability assumed, Date: 28.01.2015